Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
DOWNLOAD TO READ MORE</a></h5>" /> DOWNLOAD TO READ MORE</a></h5>" />
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREArtificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSDespite progress in the treatment and prevention of HIV – which has caused 35 million deaths since the early 1980s – there remains a pressing need for a preventive vaccine to help end the global pandemic. In this insight brief, IQVIA experts apply the company’s extensive experience in HIV, including 61 global treatment and prevention studies at 2,284 sites, and involving 30,170 subjects, to describe progress towards vaccine development. Areas of focus include the four vaccine concepts that have been tested; ongoing trials; lessons learned; and avenues of future research.
The IQVIA experts summarize recent advances in the immunopathology of HIV, encouraging new developments in vaccine research, and the very limited status of pediatric studies. They also examine the impact of pre-exposure prophylaxis (PrEP) on vaccine trials, and the role of innovative and efficient approaches such as adaptive clinical trial design.
There has been great progress in the treatment and prevention of human immunodeficiency virus (HIV) in the three decades since its discovery, with the rate of new infections slowing in many countries. However, the goal of developing a safe and effective vaccine has not yet been reached. This is due to factors including the unique nature of the HIV-1 virus and the complex human dimensions of the infection, such as same-sex and mother-to-child transmission, the breadth of cultures involved and hard-to-treat patients. While pre-exposure prophylaxis (PrEP), treatment as prevention and other preventive methodologies have greatly reduced rates of transmission, these approaches also pose ethical and scientific challenges for the design of preventive vaccine studies.
Since the early 1980s, there have been 35 million deaths due to HIV, with an estimated 78 million people infected1 (Figure 1 on the following page). Some 37 million people are currently living with HIV, of whom 30-40% are unaware that they are infected. There are 2.1 million new HIV infections each year.
Leverage numerous infectious disease and vaccine experts using best-in-class data sources and the right sites.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.